Citation Impact
Citing Papers
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
2009 Standout
Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data
1997 Standout
Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib (“Iressa”) and the DNA topoisomerase I inhibitor CPT‐11 (irinotecan) in human colorectal cancer cells
2003
Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT
2010
Etoposide: four decades of development of a topoisomerase II inhibitor
1998 Standout
Doxorubicin pathways
2010 Standout
Everolimus for Advanced Pancreatic Neuroendocrine Tumors
2011 Standout
The FGF family: biology, pathophysiology and therapy
2009 Standout
Dynamics of tumour angiogenesis: Effect of razoxane-induced growth rate slowdown
2003
Randomised controlled trial of faecal-occult-blood screening for colorectal cancer
1996 Standout
Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative.
1996 Standout
Metabolism and reactions of quinoid anticancer agents
1987
Temporal Proteome and Lipidome Profiles Reveal Hepatitis C Virus-Associated Reprogramming of Hepatocellular Metabolism and Bioenergetics
2010 StandoutNobel
Longterm Effects of Hepatic Arterial Interleukin-2–based Immunochemotherapy After Potentially Curative Resection of Colorectal Liver Metastases1
1998
Intravesical suramin: a novel agent for the treatment of superficial transitional-cell carcinoma of the bladder
1996
A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin
1999 Standout
Metabolism and action of amino acid analog anti-cancer agents
1990
An Expanded Set of Amino Acid Analogs for the Ribosomal Translation of Unnatural Peptides
2007 StandoutNobel
Cancer of the pancreas: 50 years of surgery
1987
Treatment of neuroendocrine tumors
1994
Etoposide in the management of metastatic breast cancer
1991
Preclinical antitumour activity and animal toxicology studies of rhizoxin, a novel tubulin-interacting agent
1992
Molecular mechanisms of quinone cytotoxicity
1991 Standout
Neuroendocrine gastrointestinal tumours
1996
Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function
1995
Tubulin as a target for anticancer drugs: Agents which interact with the mitotic spindle
1998 Standout
Natural products to drugs: natural product-derived compounds in clinical trials
2008 Standout
Carcinoid A Comprehensive Review
2003
Use of plasma MMP‐2 and MMP‐9 levels as a surrogate for tumour expression in colorectal cancer patients
2003
Can Hemoccult-IITM replace colonoscopy in surveillance after radical surgery for colorectal cancer and after polypectomy?
1992
Mechanisms of drug combinations: interaction and network perspectives
2009 Standout
Hereditary Colorectal Cancer
2003 Standout
Update on the treatment of neuroendocrine tumors
2003
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2010 Standout
Akt signalling in health and disease
2011 Standout
Natural compounds for cancer treatment and prevention
2009 Standout
Protein therapeutics: a summary and pharmacological classification
2007 Standout
Perspectives in cancer chemotherapy
2001
Hypoxia-Inducible Factor 1 Regulates Vascular Endothelial Growth Factor Expression in Human Pancreatic Cancer
2003 StandoutNobel
Colorectal cancer screening and surveillance: Clinical guidelines and rationale?Update based on new evidence
2003 Standout
Role of hydrogen peroxide and hydroxyl radical formation in the killing of Ehrlich tumor cells by anticancer quinones.
1986
Survival of 727 patients with single carcinomas of the large bowel
1984
Role of Quinones in Toxicology
2000 Standout
Oxygen Radicals and Human Disease
1987 Standout
Mathematical Modeling of Subgenomic Hepatitis C Virus Replication in Huh-7 Cells
2006 StandoutNobel
Continuous hyperthermic peritoneal perfusion for the prevention of peritoneal recurrence of gastric cancer: Randomized controlled study
1994
Detection and Surveillance of Colorectal Cancer
1990
The treatment of soft tissue sarcomas with focus on chemotherapy: A review
1986
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
2005 StandoutScience
Enzymatic aminoacylation of tRNA with unnatural amino acids
2006 StandoutNobel
Cantuzumab Mertansine, a Maytansinoid Immunoconjugate Directed to the CanAg Antigen: A Phase I, Pharmacokinetic, and Biologic Correlative Study
2003
VP-16-213 (etoposide): The mandrake root from Issyk-Kul
1982
Dynamics of Subgenomic Hepatitis C Virus Replicon RNA Levels in Huh-7 Cells after Exposure to Nucleoside Antimetabolites
2003
One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States
2008 Standout
Silymarin/Silybin and Chronic Liver Disease: A Marriage of Many Years
2017 Standout
A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study
1996
Resection of colorectal liver metastases
1995 Standout
Preventing and Managing Toxicities of High-Dose Methotrexate
2016 Standout
Works of O'Connell Mj being referenced
Clinical studies of biochemical modulation of 5-fluorouracil by leucovorin in patients with advanced colorectal cancer by the North Central Cancer Treatment Group and Mayo Clinic.
1987
Phase II study of triazinate and pyrazofurin in patients with advanced breast cancer previously exposed to cytotoxic chemotherapy.
1978
Phase II clinical trial of tricyclic nucleoside phosphate for advanced colorectal cancer.
1987
Phase II study of cisplatin therapy in patients with metastatic carcinoid tumor and the malignant carcinoid syndrome.
1986
Oncologic treatment of pancreatic cancer.
1983
Randomized clinical trial comparing two dose regimens of ICRF-159 in refractory malignant lymphomas.
1980
Phase II trial of maytansine in patients with advanced colorectal carcinoma.
1978
Phase II evaluation of VP-16-213 (NSC-141540) and cytembena (NSC-104801) in patients with advanced breast cancer.
1976
Pharmacokinetics of mitomycin C in patients receiving the drug alone or in combination.
1983
High-dose cytosine arabinoside and mAMSA induction and consolidation in patients with previously untreated de novo acute nonlymphocytic leukemia: Phase I Pilot Study for the Eastern Cooperative Oncology Group.
1985
Phase II trial of PALA in lymphoma: an Eastern Cooperative Oncology Group study.
1984
Phase II study of pyrazofurin in advanced colorectal carcinoma.
1977
Phase II study of VP-16-213 versus dianhydrogalactitol in patients with metastatic malignant melanoma.
1976
Phase II study of maytansine in advanced sarcomas.
1983
Postoperative follow-up of patients with carcinoma of the colon.
1983
Phase I study of N-(phosphonacetyl)-L-aspartic acid (PALA).
1980
Is hepatic infusion of chemotherapy effective treatment for liver metastases? No!
1992